| P50 | author | David Jesse Sanchez | Q64596925 |
| P2093 | author name string | Buyuan He | |
| | James T Tran | |
| P2860 | cites work | Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein | Q22010192 |
| | Latently expressed human herpesvirus 8-encoded interferon regulatory factor 2 inhibits double-stranded RNA-activated protein kinase | Q24290751 |
| | Hepatitis C virus expression suppresses interferon signaling by degrading STAT1 | Q24300002 |
| | Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain | Q24301056 |
| | Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein | Q24319002 |
| | Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells | Q24555724 |
| | Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation | Q27469500 |
| | Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response | Q27469808 |
| | Kaposi's Sarcoma Herpesvirus: twenty years after its discovery | Q28069063 |
| | Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells | Q28115799 |
| | Virus interference. II. Some properties of interferon | Q28181619 |
| | Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures | Q29615028 |
| | Mechanism of action of interferon and ribavirin in treatment of hepatitis C | Q29619805 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance | Q30391895 |
| | Epstein-Barr Virus Interferes with the Amplification of IFNα Secretion by Activating Suppressor of Cytokine Signaling 3 in Primary Human Monocytes | Q33650938 |
| | Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? | Q33922904 |
| | The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1 | Q34140181 |
| | Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial | Q34158350 |
| | HIV delays IFN-α production from human plasmacytoid dendritic cells and is associated with SYK phosphorylation | Q34302303 |
| | Quantitative Studies of Epstein-Barr Virus-Encoded MicroRNAs Provide Novel Insights into Their Regulation | Q34485302 |
| | Transcriptional and translational control in the Mammalian unfolded protein response | Q34762452 |
| | Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders | Q35026045 |
| | PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads | Q35035610 |
| | Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway | Q35111044 |
| | Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity | Q35634286 |
| | The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation | Q40644374 |
| | Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli | Q40645437 |
| | Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo | Q40705563 |
| | Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner | Q40935737 |
| | HTLV-1 Tax protein recruitment into IKKε and TBK1 kinase complexes enhances IFN-I expression. | Q41587571 |
| | T cells detect intracellular DNA but fail to induce type I IFN responses: implications for restriction of HIV replication | Q41849777 |
| | A Kaposi's sarcoma-associated herpesvirus protein that forms inhibitory complexes with type I interferon receptor subunits, Jak and STAT proteins, and blocks interferon-mediated signal transduction | Q41898857 |
| | HIV downregulates interferon-stimulated genes in primary macrophages | Q42573471 |
| | Innate immune modulation in EBV infection | Q42702857 |
| | 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. | Q42990190 |
| | An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis | Q43038009 |
| | Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor-2 inhibits type 1 interferon signalling by targeting interferon-stimulated gene factor-3. | Q43998470 |
| | Viral IL-6-induced cell proliferation and immune evasion of interferon activity | Q44218062 |
| | HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells | Q47399269 |
| | Hepatitis C virus core protein-induced miR-93-5p up-regulation inhibits interferon signaling pathway by targeting IFNAR1. | Q47548532 |
| | Interferon sensitivity-determining region of hepatitis C virus influences virus production and interferon signaling. | Q49787914 |
| | HIV-1 Promotes the Degradation of Components of the Type 1 IFN JAK/STAT Pathway and Blocks Anti-viral ISG Induction. | Q52341236 |
| | Increasing complexity of Ras signaling. | Q53429989 |
| | Regulation of interferon signaling and HCV‑RNA replication by extracellular matrix. | Q54203070 |
| | HIV blocks Type I IFN signaling through disruption of STAT1 phosphorylation | Q57036795 |
| | Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α | Q61758311 |
| | HIV-1 Treated Patients with Undetectable Viral Loads have Lower Levels of Innate Immune Responses via Cytosolic DNA Sensing Systems Compared with Healthy Uninfected Controls. | Q35647733 |
| | HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells | Q35652202 |
| | Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway | Q35689692 |
| | HIV Blocks Interferon Induction in Human Dendritic Cells and Macrophages by Dysregulation of TBK1 | Q35745385 |
| | Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a | Q35883429 |
| | Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival | Q36141691 |
| | Dendritic cell maturation, but not type I interferon exposure, restricts infection by HTLV-1, and viral transmission to T-cells. | Q36352268 |
| | Kaposi's sarcoma-associated herpesvirus microRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression | Q36363240 |
| | The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha | Q36380679 |
| | Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration | Q36495526 |
| | Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation | Q36575274 |
| | SOCS proteins, cytokine signalling and immune regulation | Q36831668 |
| | The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5 | Q37136785 |
| | DC-SIGN mediates cell-free infection and transmission of human T-cell lymphotropic virus type 1 by dendritic cells | Q37410819 |
| | Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs | Q37545050 |
| | Viral microRNAs Target a Gene Network, Inhibit STAT Activation, and Suppress Interferon Responses | Q37593352 |
| | HIV-1 immunopathogenesis in humanized mouse models | Q37676228 |
| | Distinct roles of Kaposi's sarcoma-associated herpesvirus-encoded viral interferon regulatory factors in inflammatory response and cancer | Q38115771 |
| | Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory | Q38192810 |
| | Immune control of oncogenic γ-herpesviruses | Q38587362 |
| | Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. | Q38753617 |
| | Suppression of Type I Interferon Production by Human T-Cell Leukemia Virus Type 1 Oncoprotein Tax through Inhibition of IRF3 Phosphorylation. | Q38798967 |
| | Viral Source-Independent High Susceptibility of Dendritic Cells to Human T-Cell Leukemia Virus Type 1 Infection Compared to That of T Lymphocytes. | Q38844079 |
| | HIV-1-triggered release of type I IFN by plasmacytoid dendritic cells induces BAFF production in monocytes | Q39027393 |
| | Targeting type I interferon-mediated activation restores immune function in chronic HIV infection | Q39110897 |
| | Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells | Q39138332 |
| | Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon | Q39138338 |
| | The Epstein-Barr virus-encoded LMP-1 oncoprotein negatively affects Tyk2 phosphorylation and interferon signaling in human B cells | Q39321358 |
| | Epstein-Barr virus regulates STAT1 through latent membrane protein 1. | Q39736747 |
| | The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation. | Q39806231 |
| | Epstein-Barr virus LF2: an antagonist to type I interferon. | Q39920912 |
| | Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells | Q39996982 |
| | Positive and negative regulation of type I Interferons by the human T cell leukemia virus antisense protein HBZ. | Q40097549 |
| | EBV MicroRNA BART16 Suppresses Type I IFN Signaling. | Q40239476 |
| | Inhibition of interferon signaling by the Kaposi's sarcoma-associated herpesvirus full-length viral interferon regulatory factor 2 protein. | Q40311533 |
| | The latent membrane protein 1 of Epstein-Barr virus (EBV) primes EBV latency cells for type I interferon production | Q40318357 |
| | HIV Triggers a cGAS-Dependent, Vpu- and Vpr-Regulated Type I Interferon Response in CD4+ T Cells | Q40516205 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV/AIDS | Q12199 |
| | immunology | Q101929 |
| | signal transduction | Q828130 |
| | human immunodeficiency virus infectious disease | Q18556697 |
| | RNA virus infectious disease | Q18967413 |
| | host microbial interaction | Q68260314 |
| P304 | page(s) | 8685312 | |
| P577 | publication date | 2019-04-04 | |
| P1433 | published in | Journal of Immunology Research | Q26841936 |
| P1476 | title | Manipulation of Type I Interferon Signaling by HIV and AIDS-Associated Viruses | |
| P478 | volume | 2019 | |